Figure 2
From: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Kinase inhibition profile of ABT-869 against a broader range of kinases.
Figure 2 | Journal of Hematology & Oncology
From: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Kinase inhibition profile of ABT-869 against a broader range of kinases.